NVG, LLC for ALEXION PHARMACEUTICALS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDA - rare and orphan disease issues; Prescription drug coverage and payment policies; Medical innovation issues; S. 771 Improving Access to Affordable Prescription Drugs Act; S. 637 Creating Transparency to Have Drug Rebates Unlocked Act of 2017; H. 1628 American Health Care Act of 2017; H. 2430 FDA Reauthorization Act of 2017 - PDUFA; S. 934 FDA Reauthorization Act of 2017 - PDUFA; H.R. 1231/S. 456 - Research to Accelerate Cures and Equity for Children Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA GERMAN FOSTER | — |
| PATRICIA GRIFFIN | — |
| ANDREA LARUE | — |
Copyright/Patent/Trademark CPT
Intellectual property and potential changes to the patent system, generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA LARUE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.